Business News
Paradigm Shift in MDS Treatment: Faron Pharmaceuticals Unveils Landmark Phase II Trial Data at ASCO 2025
The ability to not only extend life but also improve quality of life by reducing transfusion needs and infection rates is what sets this treatment apart